DETECTION AND PROGNOSIS OF LUNG CANCER

• US 20110117551A1
• Filed: 02/19/2009
• Published: 05/19/2011
• Est. Priority Date: 02/19/2008
• Status: Abandoned Application

• Current Assignee: Johns Hopkins University, MDxHealth Co.
• Original Assignee: Johns Hopkins University, Oncomethylome Sciences SA
• Inventors: Van Neste, Leander, Trooskens, Geert, Herman, James, Van Criekinge, Wim, Straub, Josef, Cope, Leslie, Schuebel, Kornel, Baylin, Stephen
• Application Number:
  US12/867,539
• Publication Number:
  US 20110117551A1
• Time in Patent Office: Days
• US Class Current: 435/6
• CPC Class Codes: C12Q 1/6886 for cancer immunoassay for cancer G01N33/574
• CPC Class Codes: C12Q 2600/118 Prognosis of disease development
• CPC Class Codes: C12Q 2600/154 Methylation markers
• CPC Class Codes: C12Q 2600/158 Expression markers

Abstract

Methods and tools are provided for detecting and predicting lung cancer. The methods and tools are based on epigenetic modification due to methylation of genes in lung cancer or pre-lung cancer. The tools can be assembled into kits or can be used seperately. Genes found to be epigentically silenced in association with lung cancer include ACSL6, ALS2CL, APC2, ART-S1, BEX1, BMP7, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DPYSL4, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, JAM3, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, SULF2, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655.

Claims

1. A method for identifying lung cancer or its precursor, or predisposition to lung cancer, comprising:

detecting in a test sample containing lung cells or nucleic acids from lung cells, epigenetic modification of at least one gene selected from the group consisting of DPYSL4, SULF2, JAM3, APC2, BMP7, ACSL6, ALS2CL, ARTS-1, BEX1, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655; and

identifying the test sample as containing cells that are neoplastic, precursor to neoplastic, or predisposed to neoplasia, or as containing nucleic acids from cells that are neoplastic, precursor to neoplastic, or predisposed to neoplasia.

2. The method of claim 1 wherein the test sample contains squamous cells or nucleic acids from squamous cells.

3. The method of claim 1 wherein the test sample contains adenocarcinoma cells or nucleic acids from adenocarcinoma cells.

4. The method of claim 1 wherein the test sample contains large cell carcinoma cells or nucleic acids from large cell carcinoma cells.

5. The method of claim 1 wherein the test sample contains a mixture of squamous cells, adenocarcinoma cells, and large cell carcinoma cells.

6. The method of claim 1 wherein the test sample is from a specimen selected from the group consisting of a tissue specimen, a biopsy specimen, a surgical specimen, a cytological specimen, sputum specimen, pleural fluid and a bronchoalveolar lavage.

7. The method of claim 6 wherein the test sample is from a biopsy specimen and surgical removal of neoplastic tissue is recommended to the patient

8. The method of claim 6 wherein the specimen is a surgical specimen and adjuvant chemotherapy or adjuvant radiation therapy is recommended to the patient.

9. The method of claim 1 wherein an epigenetic modification in a panel of genes comprising two, three, four or five genes is detected, wherein detection of an epigenetic change in at least one of the genes in the panel is indicative of a predisposition to, or the incidence of lung cancer.

10. The method of claim 9 wherein epigenetic modification of RASSF1A and/or SOX17 and/or HS3ST2-nor and/or NID2 and/or SFRP1 is detected

11. The method of claim 1 wherein epigenetic modification is detected by detecting methylation of a CpG dinucleotide motif in the gene.

12. The method of claim 1 wherein epigenetic modification is detected by detecting methylation of a CpG dinucleotide motif in a promoter, intron or exon of the gene.

13. The method of claim 1 wherein epigenetic modification is detected by detecting diminished expression of mRNA of the gene.

14. The method of claim 11 wherein methylation is detected by contacting at least a portion of the gene with a methylation-sensitive restriction endonuclease, said endonuclease preferentially cleaving methylated recognition sites relative to non-methylated recognition sites, whereby cleavage of the portion of the gene indicates methylation of the portion of the gene.

15. The method of claim 11 wherein methylation is detected by contacting at least a portion of the gene with a methylation-sensitive restriction endonuclease, said endonuclease preferentially cleaving non-methylated recognition sites relative to methylated recognition sites, whereby cleavage of the portion of the gene indicates non-methylation of the portion of the gene provided that the gene comprises a recognition site for the methylation-sensitive restriction endonuclease.

16. The method of claim 11 wherein methylation is detected by:

contacting at least a portion of the gene of the test sample with a chemical reagent that selectively modifies a non-methylated cytosine residue relative to a methylated cytosine residue, or selectively modifies a methylated cytosine residue relative to a non-methylated cytosine residue; and

detecting a product generated due to said contacting.

17. The method of claim 16 wherein the step of detecting a product employs amplification with at least one primer that hybridizes to a sequence comprising a modified non-methylated CpG dinucleotide motif but not to a sequence comprising an unmodified methylated CpG dinucleotide motif thereby forming amplification products.

18. The method of claim 16 wherein the step of detecting a product comprises amplification with at least one primer that hybridizes to a sequence comprising an unmodified methylated CpG dinucleotide motif but not to a sequence comprising a modified non-methylated CpG dinucleotide motif thereby forming amplification products.

19. The method of claim 16 wherein the product is detected by a method selected from the group consisting of electrophoresis, hybridization, amplification, sequencing, ligase chain reaction, chromatography, mass spectrometry, and combinations thereof.

20. The method of claim 16 wherein the chemical reagent is hydrazine.

21. The method of claim 20 further comprising cleavage of the hydrazine-contacted at least a portion of the gene with piperidine.

22. The method of claim 16 wherein the chemical reagent comprises bisulfite ions.

23. The method of claim 22 further comprising treating the bisulfite ion-contacted, at least a portion of the gene with alkali.

24. The method of claim 1 wherein the step of detecting employs amplification of at least a portion of the at least one gene using an oligonucleotide primer that specifically hybridizes under amplification conditions to a region of a gene selected from the group consisting of DPYSL4, SULF2, JAM3, APC2, BMP7, ACSL6, ALS2CL, ARTS-1, BEX1, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655;

wherein the region is within about 3 kb of said gene'"'"'s transcription start site.

25. The method of claim 1 wherein the step of detecting employs amplification of at least a portion of the at least one gene using at least one pair of oligonucleotide primers that specifically hybridizes under amplification conditions to a region of a gene selected from the group consisting of DPYSL4, SULF2, JAM3, APC2, BMP7, ACSL6, ALS2CL, ARTS-1, BEX1, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655;

wherein the region is within about 3 kb of said gene'"'"'s transcription start site.

26. The method of claim 25 wherein the region comprise, consist essentially of or consist of the sequences represented by SEQ ID NO. 129-192 and/or SEQ ID NO. 193-256 and/or SEQ ID NO. 315-329 and/or SEQ ID NO. 330-344 and/or SEQ ID NO. 408-428 and/or SEQ ID NO. 429-449 and/or SEQ ID NO. 271-277 and/or SEQ ID NO. 278-284.

27. The method of claim 1 wherein the step of detecting a product comprises amplification with at least one sense primer comprising, consisting essentially of or consisting of SEQ ID NO. 1-64 and/or SEQ ID NO. 285-299 and/or SEQ ID NO. 345-365 and/or SEQ ID NO. 257-263.

28. The method of claim 1 wherein the step of detecting a product comprises amplification with at least one antisense primer comprising, consisting essentially of or consisting of SEQ ID NO. 65-128 and/or SEQ ID NO. 300-314 and/or SEQ ID NO. 366-386 and/or SEQ ID NO. 264-270.

29. The method of claim 1 wherein the step of detecting employs amplification of at least a portion of the at least one gene, and further employs at least one oligonucleotide probe which hybridizes to an amplicon selected from the group consisting of SEQ ID NO:

129-292 and/or SEQ ID NO. 193-256 and/or SEQ ID NO. 315-329 and/or SEQ ID NO. 330-344 and/or SEQ ID NO. 408-428 and/or SEQ ID NO. 429-449 and/or SEQ ID NO. 271-277 and/or SEQ ID NO. 278-284.under amplification conditions.

30. The method of claim 29 wherein the probe comprises, consists essentially of or consists of sequences represented by SEQ ID NO. 387-407.

31. The method of claim 1 wherein the step of detecting employs amplification of at least a portion of the at least one gene and a detectable reagent which preferentially binds to double stranded DNA relative to single stranded DNA.

32. The method of claim 25 wherein an oligonucleotide probe is covalently linked to the oligonucleotide primer.

51. The method of claim 1 wherein epigenetic modification is detected by detecting hypomethylation of a CpG dinucleotide motif in the gene.

52. The method of claim 1 wherein epigenetic modification is detected by detecting hypomethylation of a CpG dinucleotide motif in a promoter of the gene.

53. The method of claim 1 wherein epigenetic modification is detected by detecting increased expression of mRNA of the gene.

33. A kit for assessing lung cancer or its precursor, or predisposition to lung cancer in a test sample containing lung cells or nucleic acids from lung cells, said kit comprising in a package:

a reagent that (a) modifies methylated cytosine residues but not non-methylated cytosine residues, or that (b) modifies non-methylated cytosine residues but not methylated cytosine residues; and

at least one pair of oligonucleotide primers that specifically hybridizes under amplification conditions to a region of a gene selected from the group consisting of DPYSL4, SULF2, JAM3, APC2, BMP7, ACSL6, ALS2CL, ARTS-1, BEX1, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655;

wherein the region is within about 3 kb of said gene'"'"'s transcription start site.

34. The kit of claim 33 wherein the at least one pair of primers is selected from Table 1 (SEQ ID NO:

1-128), FIG. 2 (SEQ ID NO;

257-270), Table 3 (SEQ ID NO;

285-314) and Table 7 (SEQ ID NO;

345-386).

35. The kit of claim 33 wherein the at least one pair of oligonucleotide primers amplifies an amplicon selected from Table 2 (SEQ ID NO:

129-256), FIG. 2 (SEQ ID NO;

271-284), Table 4 (SEQ ID NO;

315-344) and Table 8 (SEQ ID NO;

408-449).

39. The kit of claim 33 or 36 further comprising at least one oligonucleotide probe which hybridizes to an amplicon selected from the group consisting of Table 2 (SEQ ID NO:

129-256), FIG. 2 (SEQ ID NO;

271-284), Table 4 (SEQ ID NO;

315-344), Table 8 (SEQ ID NO;

408-449) under amplification conditions.

40. The kit of claim 39 wherein the oligonucleotide probe is selected from the group consisting of SEQ ID NO:

387-407.

41. The kit of claim 40 wherein the oligonucleotide probe comprises a fluorescent label.

42. The kit of claim 40 wherein the oligonucleotide probe comprises a fluorescence quenching agent.

43. The kit of claim 40 wherein the oligonucleotide probe comprises a fluorescent label and fluorescence quenching agent.

44. The kit of claim 33 or 36 which comprises a detectable reagent which preferentially binds to double stranded DNA relative to single stranded DNA.

45. The kit of claim 33 or 36 further comprising a DNA polymerase for amplifying DNA.

46. The kit of claim 33 or 36 further comprising at least one oligonucleotide probe which is covalently linked to at least one of said oligonucleotide primers.

48. The polynucleotide of claim 41 which is detectably labeled.

49. The polynucleotide of claim 41 which is detectably labeled with a fluorescent label.

50. The isolated polynucleotide of claim 41 which consists of the selected nucleotide sequence.

36. A kit for assessing lung cancer or its precursor, or predisposition to lung cancer in a test sample containing lung cells or nucleic acids from lung cells, said kit comprising in a package:

at least two pairs of oligonucleotide primers that specifically hybridize under amplification conditions to a region of a gene selected from the group consisting of DPYSL4, SULF2, JAM3, APC2, BMP7, ACSL6, ALS2CL, ARTS-1, BEX1, BNIP3, CBR3, CD248, CD44, CHD5, DLK1, DSC2, EDNRB, EPB41L3, EPHB6, ERBB3, FBLN2, FBN2, FOXL2, GNAS, GSTP1, HS3ST2, HPN, IGFBP7, IRF7, LOX, LY6D, LY6K, MACF1, MCAM, NCBP1, NEFH, NID2, PCDHB15, PCDHGA12, PFKP, PGRMC1, PHACTR3, PHKA2, POMC, PRKCA, PSEN1, RASSF1A, RASSF2, RBP1, RRAD, SFRP1, SGK, SOD3, SOX17, TIMP3, TJP2, TRPV2, UCHL1, WDR69, ZFP42, ZNF442, and ZNF655;

wherein the region is within about 3 kb of said gene'"'"'s transcription start site.

37. The kit of claim 36 wherein the at least two pairs of primers are selected from SEQ ID NO:

1-128 (Table

     1), SEQ ID NO;

257-270 (FIG. 2), SEQ ID NO;

285-314 (Table

     3), SEQ ID NO;

345-386 (Table

     7).

38. The kit of claim 36 wherein the at least two pairs of oligonucleotide primers amplify amplicons selected from Table 2 (SEQ ID NO:

129-256), FIG. 2 (SEQ ID NO;

271-284), Table 4 (SEQ ID NO;

315-344) and Table 8 (SEQ ID NO;

408-449).

47. An isolated polynucleotide comprising a nucleotide sequence selected from the group consisting of SEQ ID NO:

1-449.